

## **Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC**

**Leuven, BELGIË – 29 mei 2026 – 18u00 CET** [Oxurion NV](#) (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving<sup>1</sup>, de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving een transparantiekennisgeving op 27 mei 2026 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 26 mei 2026 515.805 aandelen van de toen uitstaande 88.691.312 aandelen bezat en dus onder de drempel (3%) kwam door de verkoop van stemrechtverlenende effecten.

Oxurion ontving een transparantiekennisgeving op 28 mei 2026 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 28 mei 2026 21.925.975 aandelen van de toen uitstaande 111.049.581 aandelen bezat en dus boven de drempel (15%) kwam door de aankoop van stemrechtverlenende effecten.

### **Over Oxurion**

Oxurion NV (Euronext Brussel: OXUR) is een bedrijf dat zich specialiseert in het verwerven van meerderheidsbelangen in veelbelovende Europese farmaceutische onderaannemers. Oxurion heeft de ambitie om een geïntegreerde groep van onderaannemers op te bouwen die de gezondheidszorgsector bedient. Het hoofdkantoor van de groep is gevestigd in Leuven, België. Meer informatie is beschikbaar op [www.oxurion.com](http://www.oxurion.com).

### ***Belangrijke informatie over toekomstgerichte verklaringen***

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

### **Voor meer informatie kunt u contact opnemen met:**

<p>Oxurion NV Pascal Ghoson, Chief Executive Officer <a href="mailto:Pascal.ghoson@oxurion.com">Pascal.ghoson@oxurion.com</a></p>
---

1. Art 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

# ANNEX 1

## 1) Status of the notification

Final

## 2) Issuer

Name: OXURION  
 Identification number: 0881-820-924

## 3) Reason for the notification

Downward crossing of the lowest threshold  
 Acquisition or disposal of voting securities or voting rights

## 4) Notification by

A person that notifies alone

## 5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

## 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

**i** Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

## 7) Date on which the threshold is crossed

28/05/2028 (DD/MM/YYYY)

## 8) Threshold that is crossed (in %)

3

**i** If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

## 9) Denominator

88,891,312

**i** Please enter the denominator before filling in the data

## 10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	4,320,175	515,805		0.58%	
<b>TOTAL</b>		<b>515,805</b>	<b>0</b>	<b>0.58%</b>	<b>0.00%</b>

**i** Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone".  
 For groups, start with the ultimate controlling natural person or legal entity.  
 The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	<b>CALCULATE</b>	515,805	0.58%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM


Holder  will cease to hold / will hold again  voting rights as of  (DD/MM/YYYY)

13) Additional information

On 19 May 2026 (with settlement date on 21 May 2026), Atlas Special Opportunities II LLC sold 287,307 shares in Oxurion NV, as a result of which its shareholding decreased to 4,320,175 shares (= 4.871%, denominator = 88,691,312)  
 On 22 May 2026 (with settlement date on 26 May 2026), Atlas Special Opportunities II LLC sold 3,804,370 shares in Oxurion NV, as a result of which its shareholding decreased to 515,805 shares (= 0.582%, denominator = 88,691,312)

Done at  New York  
 On  27/05/2026 (DD/MM/YYYY)

Name & capacity  Patrick Vance, Proxyholder

Signature  

For security reasons, the unsigned form in xlsx format should be transmitted to [trp.fin@fsma.be](mailto:trp.fin@fsma.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in PDF format should also be transmitted.

## ANNEX 2

<b>FSMA</b> <small>FINANCIAL SERVICES AND MARKETS AUTHORITY</small>	<b>Transparency notification</b> <b>Form TR-1 BE</b> <b>PART I</b>
--	--

### 1) Status of the notification

Final

### 2) Issuer

Name: OXURION  
 Identification number: 0881-620-924

### 3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

### 4) Notification by

A person that notifies alone

### 5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

### 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

### 7) Date on which the threshold is crossed

28/05/2026 (DD/MM/YYYY)

### 8) Threshold that is crossed (in %)

15

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

### 9) Denominator

111,049,561

Please enter the denominator before filling in the data

### 10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to the securities	Not linked to the securities	Linked to the securities	Not linked to the securities
Atlas Special Opportunities II LLC	515,805	21,925,975		19.74%	
<b>TOTAL</b>		<b>21,925,975</b>	<b>0</b>	<b>19.74%</b>	<b>0.00%</b>

Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone".  
 For groups, start with the ultimate controlling natural person or legal entity.  
 The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments		After the transaction				
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	21,925,975
		19.74%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  voting rights as of  (DD/MM/YYYY)

13) Additional information

On 22 May 2026 (with settlement date on 26 May 2026), Atlas Special Opportunities II LLC sold 3,804,370 shares in Oxurion NV, as a result of which its shareholding decreased to 515,805 shares (= 0.582%, denominator = 88,691,312)

On 25 May 2026 (with settlement date on 27 May 2026), Atlas Special Opportunities II LLC sold 515,805 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.000%, denominator = 88,691,312)


On 26 May 2026 (with settlement date on 27 May 2026), Atlas Special Opportunities II LLC acquired 22,358,269 shares in Oxurion NV through conversion, as a result of which its shareholding increased to 22,358,269 shares (= 20.134%, denominator = 111,049,581)

On 26 May 2026 (with settlement date on 28 May 2026), Atlas Special Opportunities II LLC sold 432,294 shares in Oxurion NV, as a result of which its shareholding decreased to 21,925,975 shares (= 19.744%, denominator = 111,049,581)

Done at  New York

On  28/05/2026 (DD/MM/YYYY)

Name & capacity  Patrick Vance, Proxyholder

Signature  

For security reasons, the unsigned form in xlsx format should be transmitted to [trp.fin@fsma.be](mailto:trp.fin@fsma.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in PDF format should also be transmitted.